CLAIMS

1. Recombinant protein comprising the extracellular domain derived from Robo1 protein or a part of this domain, a linker and an immunoglobulin Fc domain from human immunoglobulin G4, in which the Fc domain contains the S241P and L248E mutations and in which the lysine located in the C-terminal position is absent, for use in the treatment of hepatocarcinoma~~cancer~~.

~~2. Recombinant protein for use according to Claim 1, wherein said cancer is hepatocarcinoma.~~

~~3.~~2. Recombinant protein for use according to ~~either one of~~ Claims 1 ~~or 2~~, which does not inhibit endothelial cell proliferation.

~~4.~~3. Recombinant protein for use according to any one of Claims 1 to 2~~3~~, wherein said extracellular domain is an extracellular domain derived from isoform b of the Robo1 protein.

~~5.~~4. Recombinant protein for use according to Claim 3~~4~~, in which the extracellular domain of Robo1 or part thereof consists in the Ig1 and Ig2 immunoglobulin domains of said extracellular domain.

~~6.~~5. Recombinant protein for use according to Claim 4~~5~~, in which the extracellular domain of Robo1 has at least 80 percent identity with the sequence SEQ ID NO.2.

~~7. Recombinant protein for use according to any one of the preceding Claims, wherein said protein further comprises a linker and an immunoglobulin Fc domain.~~

~~8. Recombinant protein for use according to Claim 7, in which the Fc domain comes from human immunoglobulin G4.~~

~~9. Recombinant protein for use according to Claim 8, in which the Fc domain contains the S241P and L248E mutations and in which the lysine located in the C-terminal position is absent.~~

~~10.~~6. Recombinant protein for use according any one of the preceding Claims, the sequence of which has at least 80 percent identity with the sequence SEQ ID NO. 4, SEQ ID NO.6 or SEQ ID NO. 24.

~~11.~~ 7. Recombinant protein for use according any one of the preceding Claims, wherein said protein has been produced by transfection of expression plasmids encoding a protein of~~the sequence of which is the~~ sequence SEQ ID NO. 4, SEQ ID NO.6 or SEQ ID NO. 24 into CHO cells, recovered from the culture supernatant, and purified.

8. Use of a recombinant protein comprising the extracellular domain derived from Robo1 protein or a part of this domain, a linker and an immunoglobulin Fc domain from human immunoglobulin G4, in which the Fc domain contains the S241P and L248E mutations and in which the lysine located in the C-terminal position is absent, in the manufacture of a medicament for the treatment of hepatocarcinoma.

9. The use according to claim 8, wherein the recombinant protein does not inhibit endothelial cell proliferation.

10. The use according to any one of claims 8 to 9, wherein said extracellular domain is an extracellular domain derived from isoform b of the Robo1 protein.

11. The use according to claim 10, in which the extracellular domain of Robo1 or part thereof consists in the Ig1 and Ig2 immunoglobulin domains of said extracellular domain.

12. The use according to claim 11, in which the extracellular domain of Robo1 has at least 80 percent identity with the sequence SEQ ID NO.2.

13. The use according to any one of claims 8 to 12, the sequence of which has at least 80 percent identity with the sequence SEQ ID NO. 4, SEQ ID NO.6 or SEQ ID NO. 24.

14. The use according to any one of claims 8 to 13, wherein said protein has been produced by transfection of expression plasmids encoding a protein of sequence SEQ ID NO. 4, SEQ ID NO.6 or SEQ ID NO. 24 into CHO cells, recovered from the culture supernatant, and purified.